MindWalk
American AI drug-discovery company (Nasdaq: HYFT), formerly ImmunoPrecise Antibodies
HYFT Nasdaq
ISIN CA45257F2008 SEC CIK 1715925
Follow MindWalk
Weekly email: filings, results
Revenue, last quarter
CAD 4.2M
+52.4% vs same quarter last year
Net income
−CAD 3.9M
+81.7% vs same quarter last year
EPS, diluted
-
Operating cash flow
−CAD 3M
−147% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | CAD 24.5M | −CAD 30.2M |
| FY24 | CAD 24.5M | −CAD 26.1M |
| FY23 | CAD 20.7M | −CAD 26.6M |
| FY22 | CAD 19.4M | −CAD 16.7M |
| FY21 | CAD 17.9M | −CAD 7.3M |
| FY20 | CAD 14.1M | −CAD 4.9M |
| FY19 | - | - |
- Gross margin
- Net margin
Show the numbers
| Year | Gross margin | Net margin |
|---|---|---|
| FY25 | 55.3% | −123.3% |
| FY24 | 49.2% | −106.5% |
| FY23 | 56% | −128.5% |
| FY22 | 56.7% | −86.3% |
| FY21 | 64.4% | −41% |
| FY20 | 57.1% | −35.2% |
| FY19 | - | - |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | −CAD 7.2M |
| FY24 | −CAD 4.6M |
| FY23 | −CAD 21.3M |
| FY22 | −CAD 11M |
| FY21 | −CAD 2M |
| FY20 | −CAD 1.8M |
| FY19 | - |
- MindWalk
- Healthcare median
Show the numbers
| Year | MindWalk | Healthcare median |
|---|---|---|
| FY25 | −123.3% | −30.6% |
| FY24 | −106.5% | −47% |
| FY23 | −128.5% | −58% |
| FY22 | −86.3% | −80.4% |
| FY21 | −41% | −71.9% |
| FY20 | −35.2% | −62.2% |
| FY19 | - | −46.3% |